Inonu University, Turgut Ozal Medical Center, Department of Radiology, Malatya, Turkey.
Inonu University, Liver Transplantation Institute, Malatya, Turkey.
Transplant Proc. 2021 Jan-Feb;53(1):104-110. doi: 10.1016/j.transproceed.2020.08.031. Epub 2020 Sep 9.
Splenomegaly and hypersplenism caused by liver failure increase the mortality and morbidity of patients even after liver transplantation if they do not regress. We evaluated the relation of splenic volume change and transplanted liver function.
A total of 59 of 207 pediatric patients who had liver transplantation between 2013 and 2018 in our institute were evaluated. The relation of spleen volume changes (splenic volume to standard splenic volume ratio [SV/SSV]) were measured at 0, 1, 6, 12, 24, and 36 months of follow-up by constructing electronic three-dimensional structure of the spleen at dynamic computed tomography (CT), and the course of liver functions were evaluated.
The SV/SSV ratio decreases in the first postoperative 6 months. After 6 months, SV increases and SV/SSV increases gradually. In a normal functioning graft, SV/SSV significantly decreased in all time points (P < .001). In patients with adverse events, SV/SSV started to increase after 6 months. In patients with fulminant hepatic failure, SV/SSV started to increase after postoperative 6 months. Adverse events in patients with fulminant hepatic failure were more than the patients with chronic liver disease (58% vs 28%). There was an inverse correlation between SV/SSV and thrombocyte levels (P < .001).
SV/SSV seems to be correlated to the adverse events (ie, rejection). Together with thrombocyte levels, it can be used as a noninvasive test for follow-up of transplant patients in terms of adverse events in graft function.
肝功能衰竭引起的脾肿大和脾功能亢进即使在肝移植后也会增加患者的死亡率和发病率,如果不消退的话。我们评估了脾体积变化与移植肝功能的关系。
我们评估了 2013 年至 2018 年在我院接受肝移植的 207 例儿科患者中的 59 例。通过在动态 CT 上构建电子三维脾脏结构,在 0、1、6、12、24 和 36 个月的随访中测量脾脏体积变化(脾脏体积与标准脾脏体积比 [SV/SSV]),并评估肝功能的变化。
SV/SSV 比值在术后前 6 个月内下降。6 个月后,SV 增加,SV/SSV 逐渐增加。在功能正常的移植物中,SV/SSV 在所有时间点均显著降低(P<.001)。在发生不良事件的患者中,SV/SSV 在 6 个月后开始增加。在暴发性肝衰竭患者中,SV/SSV 在术后 6 个月后开始增加。暴发性肝衰竭患者的不良事件多于慢性肝病患者(58%比 28%)。SV/SSV 与血小板水平呈负相关(P<.001)。
SV/SSV 似乎与不良事件(即排斥反应)相关。与血小板水平一起,它可以作为一种非侵入性的检测方法,用于监测移植患者的不良事件和移植物功能。